Q1: 2026-05-05 Earnings Summary

EPS of -$0.09 misses by $0.02

|

Revenue of

$0.00

beats by $0.00

Trevi Therapeutics, Inc. ( TRVI ) Bank of America Global Healthcare Conference 2026 May 12, 2026 8:15 PM EDT

Company Participants

Jennifer Good - Co-Founder, CEO, President, & Director

Presentation

Jennifer Good

Co-Founder, CEO, President, & Director

We have some legitimate contenders in here. I'm going to tell you in 15 minutes, a quick overview of Trevi. So Trevi, we have a single asset, nalbuphine ER. We are focused in difficult-to-treat chronic cough conditions. For those of you that have been following cough, it's been a difficult area. There's a huge unmet need. I think what we've brought to the space is a differentiated mechanism that not only works peripherally in the lung, but importantly, centrally in the brain. We are the only investigational therapy that's had positive data in both idiopathic pulmonary fibrosis related cough, but also refractory chronic cough.…